MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination전장 바이러스 단백질을 발현하는 MCMV 기반 백신 벡터는 단회 백신 접종 시 장기간 체액성 면역 보호를 제공합니다Article Published on 2022-01-072022-09-12 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome antigenic peptide caused CD8 Cellular immune response cellular immunity clinically CMV coronavirus cytomegalovirus Effect elicit excluded expressing full-length humoral humoral imunity Humoral response immune protection immune response Immunological memory induce Influenza influenza A virus Influenza virus injection investigated medical need memory T cells mice morbidity and mortality murine neutralizing antibody responses Pandemics Pathogens Population Protective Protein public health Respiratory pathogens robust SARS-CoV-2 T cell the spike protein vaccination Vaccine vaccine vector Vaccines vector Viral protein [DOI] 10.1038/s41423-021-00814-5 PMC 바로가기 [Article Type] Article
Evaluation of Clinical and Immune Responses in Recovered Children with Mild COVID-19가벼운 코비드 19를 가진 회수 된 어린이의 임상 및 면역 반응 평가Article Published on 2022-01-042022-09-01 Journal: Viruses [Category] 변종, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome addition age Antibody Response Asymptomatic caused Cell Cellular immune response children clinical Clinical data collected consequence coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 cases detectable discharged Health highlight IFN-γ IgG IgM immune memory immune responses Infant Infants Infection Inflammation less lung imaging abnormalities lung imaging abnormality lung lesion lung lesions memory memory B memory B cell memory T cell memory T cells mild COVID-19 Neutralizing antibodies neutralizing antibody no significant difference nucleocapsid protein recovered recovered children respiratory response returned robust SARS-CoV-2 secretion severe acute respiratory syndrome Coronavirus Spread symptom onset symptomatic T cells variant variants whole blood sample [DOI] 10.3390/v14010085 PMC 바로가기 [Article Type] Article
Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities장기요양시설 입소자의 SARS-CoV-2-중화항체 동역학Article Published on 2022-01-012022-09-12 Journal: The journal of nutrition, health & aging [Category] SARS, 진단, [키워드] affected Analysis Antibody titer appear BNT162b2 Care Cellular immune response COVID-19 elderly Epidemic evaluate facility Follow-up high risk Immunity immunosenescence Kinetics material median morbidity Mortality NAb titer NAbs neutralization test neutralizing antibody nine nursing homes outbreak participant Particle Patient patients Pfizer positive serology Quantitative remained resident retroviral S glycoprotein SARS-CoV-2 SARS-COV-2 infection Seroconversion serological Serological assay Serological testing seronegative shown significant difference statistically significant susceptible T cell the SARS-CoV-2 virus timepoint university vaccination Vaccination strategy Vaccine [DOI] 10.1007/s12603-021-1713-4 PMC 바로가기 [Article Type] Article
Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients혈액 투석 및 신장 이식 환자에서 중증 급성 호흡기 증후군 코로나바이러스-2 백신 접종에 대한 체액 및 세포 면역 반응Review Published on 2022-01-012022-09-12 Journal: Nephrology (Carlton, Vic.) [Category] SARS, 진단, [키워드] acute respiratory syndrome article Cellular immune response clinical immunology Cohort conducted confounders Coronavirus-2 country COVID-19 disease eligible ESRD excluded Follow-up General population group Haemodialysis Haemodialysis patient healthy control healthy controls humoral immune IMPROVE kidney kidney transplant Kidney transplantation Meta-analysis meta-regression outcome Patient patients proportion proportions ranged renal renal replacement therapy reported Responder response SARS-CoV-2 searched significantly lower vaccination Vaccines [DOI] 10.1111/nep.13974 PMC 바로가기 [Article Type] Review
Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell DepletionB 세포 고갈이 있는 자가 면역 질환 환자의 SARS-CoV-2 감염 및 예방 접종에 대한 체액 및 세포 면역 반응Article Published on 2022-01-012022-09-11 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] SARS, 치료법, [키워드] antibodies Antibody Response Antibody responses Autoimmune disease autoimmune disease patient Autoimmune diseases B cell B cells block Cellular immune response Control controls Critical Depletion enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot assay expected healthy control healthy controls humoral Humoral and cellular immune responses humoral immune response immune responses Infection interferon interferon-γ nucleocapsid nucleocapsid protein Nucleocapsid proteins Patient protective immunity response SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination T cell T cell response T cell responses tested the patient the SARS-CoV-2 therapeutic These data vaccination were assessed [DOI] 10.1002/art.41914 PMC 바로가기 [Article Type] Article
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases면역 매개 염증성 류마티스 질환 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 면역 반응Article Published on 2022-01-012022-09-12 Journal: RMD Open [Category] SARS, 진단, [키워드] abatacept age Autoimmune Autoimmune diseases B-cell CD4 CD8 Cellular immune response cellular response Cellular responses correlated COVID-19 cumulative deleterious effects demonstrated depleting dose drug Effect Efficacy elicited Gender glucocorticoid healthy controls humoral humoral responses identify immune response immune system immune system diseases Immune-mediated Immunosuppression immunotherapies infections Inflammatory introduced investigated leflunomide methotrexate mRNA mRNA vaccine mRNA vaccines naïve Patient patients with SARS-CoV-2 phase III trial preserved receiving reduce reduced responders response rheumatic disease rituximab SARS-CoV-2 SARS-CoV-2 vaccine selected Seroconversion seroconversion rate T-cell immune response T-lymphocyte subsets the vaccine Therapies therapy titre treated two-dose regimen vaccination Vaccine were excluded [DOI] 10.1136/rmdopen-2021-001898 PMC 바로가기 [Article Type] Article
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19강력한 체액성 및 세포성 면역 반응 및 경증 COVID-19 무증상에서 최소 8개월 후 재감염 위험 낮음Article Published on 2022-01-012022-09-11 Journal: Journal of internal medicine [Category] SARS, 진단, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody Asymptomatic asymptomatic to mild Cell Cellular immune response Chain Reaction Cohort coronavirus COVID-19 COVID-19 disease severity COVID-19 patient COVID-19 patients cumulative cumulative incidence detectable immune response Follow-up HCW healthcare worker hospitalized COVID-19 patients humoral Humoral response immune responses incidence Inclusion Infection initial investigated long-term immunity majority memory T memory T cell Mild PCR PCR-confirmed polymerase chain polymerase chain reaction positive positive individual protective effect reduced risk Reinfection remained respiratory response resulting risk SARS-CoV-2 SARS-COV-2 infection seroconverted seronegative seropositive severe acute respiratory syndrome Coronavirus Severe infection spike IgG Support T cell T cell responses vaccination [DOI] 10.1111/joim.13387 PMC 바로가기 [Article Type] Article
Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant RecipientsArticle Published on 2021-12-212022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibodies AZD1222 BNT162b2 booster cellular Cellular immune response Cohort convalescent patient coronavirus COVID-19 COVID-19 vaccination criterion detectable dialysis elicited healthy individual healthy individuals humoral IgG titer immune immune response immune system immunization Immunosuppression independent risk factor initial interferon-γ Kidney disease kidney transplant Linear regression model medication mRNA-1273 Patient patient subgroup performed protection quantified reactivity receiving recipient recipients response Retrospective analysis SARS-CoV-2 separated Seroconversion seroconversion rate serological significantly lower titer Transplant vaccination [DOI] 10.3390/microorganisms10010004 PMC 바로가기 [Article Type] Article
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants이종 Chadox1 NCOV-19 및 BNT162B2 프라임-부스트 백신 접종은 유능한 SARS-COV-2 변이체에 대한 강력한 중화 항체 반응 및 T 세포 반응성을 유도합니다.Clinical Trial Published on 2021-12-172022-08-13 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] addition Administered Adverse reactions All participants Alpha analysed antibody titres ART Arts B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta BNT162b2 boost CD4 CD8 Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 COVID-19 vaccination Delta dominant elicit elicited European evaluate finding followed by foundation funding Gamma Germany Heterologous heterologous vaccination homologous Horizon humoral immune immune responses Immunity immunogenic Immunological response immunological responses individual induce Lower median mRNA-based vaccine mRNA-based vaccines nCoV neutralization neutralized Neutralizing activity Neutralizing antibody response no difference offer P.1 participant peptide peptides prevalent Protective reactive reactivity reactogenicity receiving recognize regimen Research resulting retained Robert Koch SARS-CoV-2 spike peptide SARS-CoV-2 variant SARS-CoV-2 variants Science sera Serious Adverse Event Serious Adverse Events serological data significantly Symptom T cell T cells tested titre union vaccination variant variants variants of concern Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.ebiom.2021.103761 PMC 바로가기 [Article Type] Clinical Trial
Durability of SARS-CoV-2-Specific T-Cell Responses at 12 Months PostinfectionArticle Published on 2021-12-152022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 바이오마커, 진단, 치료기술, [키워드] 12 months acute illness acute respiratory syndrome age antibody CD4 T cell Cellular immune response cellular response clinical outcomes coronavirus coronavirus disease COVID-19 Cytotoxic T cell cytotoxicity detectable disease disease severity Durability ENhance flow cytometry Frequency identify Immunity induce Infection influence intracellular cytokine staining investigated magnitude memory memory T cell Month multisite natural infection participant Peripheral blood Phenotypes polyfunctionality Postinfection prospective cohort study representing response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody SARS-CoV-2-specific T cell severe disease T cell therapeutic interventions [DOI] 10.1093/infdis/jiab543 PMC 바로가기